参考文献

［1] VELAZQUEZ E J，MORROW D A，DEVORE A D，et al. PIONEER-HF Investigators. Angiotensin- Neprilysin Inhibition in Acute Decompensated Heart Failure ［J］. N Engl J Med，2019，380（6）：539- 548.

［2] WACHTER R，SENNI M，BELOHLAVEK J，et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge：primary results of the randomised TRANSITION study ［J］. Eur J Heart Fail，2019，21（8）：998-1007.

［3] SOLOMON S D，MCMURRAY J J V，ANAND I S，et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction ［J］. N Engl J Med，2019，381（17）：1609-1620.

［4] ZINMAN B，WANNER C，LACHIN J M，et al. Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes ［J］.N Engl J Med，2015，373（22）：2117-2128.

［5] NEAL B，PERKOVIC V，MAHAFFEY K W，et al. Canagliflozin and cardiovaascular and renal events in type 2 diabets ［J］. N Engl J Med，2017，377（7）：644-657.

［6] MCMURRAY J J V，SOLOMON S D，INZUCCHI S E，et al. Dapagliflozin in patients with heart failure and reduced ejection fraction ［J］. N Engl J Med，2019，381（21）：1995-2008.

［7] PETRIE M，VERMA S，DOCHERTY K F，et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes ［J］. JAMA，2020，323（14）：1353-1368.

［8] ZELNIKER T A，BRAUNWALD E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter-2 inhibitors：JACC state-of-the-art review ［J］. J Am Coll Cardiol，2020，75（4）：422-434.

［9] STASCH J P，PACHER P，EVGENOV O V. Soluble guanylate cyclase as an emerging theraputic target in cardiopulmonary disease ［J］. Circulation，2011，123（20）：2263-2273.

［10] ARMSTRONG P W，PIESKE B，ANSTROM K J，et al. Vericiguat in patients with heart failure and reduced ejection fraction［J］. N Engl J Med，2020，382（20）：1883-1893.

［11] KHAN H，METRA M，BLAIR J E，et al. Istaroxime，a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition：a new promising treatment for acute heart failure syndromes ？［J］. Heart Fail Rev，2009，14（4）：277-287.

［12] CARUBELLI V，ZHANG Y，METRA M，et al. Istaroxime ADHF Trial Group. Treatment with 24 hour istaroxime infusion in patients hospitalized for acute heart failure：a randomised，placebo-controlled trial ［J］. Eur J Heart Fail，2020.

［13] LIU L C，DORHOUT B，VAN DER MEER P，et al. Omecamtiv mecarbil：a new cardiac myosin activator for the treatment of heart failure ［J］. Expert Opin Investig Drugs，2016，25（1）：117-127.

［14] TEERLINK J R，FELKER G M，MCMURRAY J J V，et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure：the ATOMIC-AHF study ［J］. J Am Coll Cardiol，2016，67（12）：1444-1455.

［15] TEERLINK J R，FELKER G M，MCMURRAY J J V，et al. Chronic oral study of myosin activation to increase contractility in heart failure（COSMIC-HF）：a phase 2，pharmacokinetic，randomised，placebo-controlled trial ［J］. Lancet，2016，388（10062）：2895-2903.

［16] TEERLINK J R，DIAZ R，FELKER G M，et al. Omecamtiv Mecarbil in chronic heart failure with reduced ejection fraction：rationale and design of GALACTIC-HF ［J］. JACC Heart Fail，2020，8（4）：329-340.

［17] TIETJENS J，TEERLINK J R. Serelaxin and acute heart failure ［J］. Heart，2016，102（2）：95-99.

［18] TEERLINK J R，COTTER G，DAVISON B A，et al. Serelaxin，recombinant human relaxin-2，for treatment of acute heart failure（RELAX-AHF）：a randomised，placebo-controlled trial ［J］. Lancet，2013，381（9860）：29-39.

［19] METRA M，TEELINK J R，COTTER G，et al. Effects of serelaxin in patients with acute heart failure ［J］. N Engl J Med，2019，381（8）：716-726.

［20] TEERLINK J R，DAVISON B A，COTTER G，et al. Effects of serelaxin in patients admitted for acute heart failure：a metaanalysis ［J］. Eur J Heart Fail，2020，22（2）：315-329.